Genetic host factors in Helicobacter pylori -induced carcinogenesis: Emerging new paradigms

Mommersteeg, Michiel C.; Yu, Jun; Peppelenbosch, Maikel P.; Fuhler, Gwenny M.

doi:10.1016/j.bbcan.2017.11.003

Cited by 75 publications

(71 citation statements)

References 156 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cinobufagin is extracted from Chan Su and was used in Chinese medicine to treat tumors for many years. Cinobufagin has been demonstrated to induce apoptosis in human leukemia, hepatocellular carcinoma and prostate cancer (7,8). Currently, cinobufagin is widely used in the treatment of tumor diseases.…”

Section: Discussionmentioning

confidence: 99%

“…Bufalin, resibufogenin, and cinobufagin are the active ingredients in Chan Su. To date, several reports have detailed the antitumor effects of cinobufagin in gastric cancer (6)(7)(8). Additionally, research has demonstrated that cinobufagin may trigger apoptosis and autophagic cell death in gastric cancer via activation of the reactive oxygen species (ROS)/JNK/p38 axis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Inhibition of autophagy enhances cinobufagin‑induced apoptosis in gastric cancer

et al. 2018

View full text Add to dashboard Cite

Cinobufagin is a cardiotoxic bufanolide steroid secreted by the Asiatic toad Bufo gargarizans. Cinobufagin is one of the active ingredients in the anticancer Chinese medicine called Chan Su, which was demonstrated to be an effective treatment for gastric cancer. Increasing evidence shows that inhibition of autophagy has a pro-apoptotic effect on human gastric cancer cells. The aim of the present study was to investigate the relationship between cinobufagin, autophagy and apoptosis in gastric cancer. Autophagy was induced or inhibited in the human gastric cancer cell line SGC-7901 by incubation in HBSS media or by treatment with 3-methyladenine or ATG5 siRNA, respectively. Following treatment, the levels of apoptosis, apoptotic proteins, reactive oxygen species (ROS), and mitochondrial membrane potential were compared between the conditions. As anticipated, we found that cinobufagin increased apoptosis in SGC-7901 cells. Notably, inhibition of autophagy, monitored by the absence of the autophagosome marker LC3-II, also enhanced cell apoptosis. This effect was reversed when autophagy was induced by incubation in HBSS media. Enhanced expression of pro-apoptotic indicators, including BAX, cytosolic cytochrome c, cleaved PARP, caspase-3 and caspase-9, was detected when autophagy was suppressed. Increased pro-apoptotic protein expression was accompanied by disrupted mitochondrial membrane potential and elevated ROS production. Altogether, these data suggest that inhibition of autophagy enhances the anticancer action of cinobufagin through increased apoptosis of gastric cancer cells. Moreover, these effects may be partly mediated by ROS generation and the activation of the mitochondrial programmed cell death pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Inhibition of autophagy enhances cinobufagin‑induced apoptosis in gastric cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…International Agency for Research of Cancer and the World Health Organisation have classified H pylori as a group I carcinogen since H pylori is the major aetiological factor for gastric cancer, which can be prevented by early eradication before metaplasia and atrophy occur. Moreover, H pylori eradication in high‐risk areas reduces the risk of gastric cancer in asymptomatic individuals . When determining appropriate H pylori eradication treatment, several factors are taken into consideration.…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, H pylori eradication in high-risk areas reduces the risk of gastric cancer in asymptomatic individuals. 9,10 When determining appropriate H pylori eradication treatment, several factors are taken into consideration. These include the local susceptibility of the bacteria to different antibiotics and patient history of penicillin allergy or antibiotic intake.…”

mentioning

confidence: 99%

Correlation of registered drug packs with Maastricht V/Florence Consensus Report and national treatment guidelines for management of Helicobacter pylori infection

Jukic

Rušić

Vuković

et al. 2019

Basic Clin Pharma Tox

View full text Add to dashboard Cite

High prevalence of Helicobacter pylori infection, the complexity for its treatment, poor correlation of registered drug packs or poor patient adherence to the treatment may contribute to antibiotic resistance and healthcare costs. The aim of the present study was to investigate whether registered drug packs are in accordance with European and national guidelines for H pylori eradication with reference to the number of drug units. In this study, we considered treatment options for the management of H pylori infection recommended by the Maastricht V/Florence Consensus Report and by national guidelines in the United Kingdom (UK), Croatia, Italy and Slovenia for adults. Drugs proposed by the guidelines were identified in national drug databases in July of 2019. When considering correlation for 10‐day treatment regimens, drug packs registered in Croatia could not be matched with recommendations for sequential therapies. A number of proposed treatments could not be matched due to small variety of drug packs in Croatia. Drug packs registered in the UK more often matched recommended 14‐day treatment regimens and national guidelines. With reference to European guidelines, 10‐day treatments could more frequently be matched in Italy and in Slovenia. Furthermore, results of this study indicate that there is smaller variety in drug pack sizes registered in Croatia and Slovenia when compared to UK and Italy. Considering poor correlation of drug packs with treatment guidelines for H pylori, adherence to antimicrobial treatment and proper disposal of antimicrobials is warrant. Discussing adherence to antimicrobial treatment with patients should be introduced as a standard of patient care and education.

show abstract

“…Большое значение уделяется генетическим особенностям организма человека, модулирующим эффекты H. pylori и факторов внешней среды. В каче-стве факторов риска рака желудка идентифицирован ряд полиморфизмов генов, ответственных за воспалительный ответ, репарацию ДНК, онкосупрессию и метаболизм канцерогенов [28,29]. Тем не менее клиническое значение полиморфизмов в отношении спорадического рака желудка остается до конца неопределенным.…”

Section: генетические особенности организма человекаunclassified

Prophylaxis and early diagnosis of stomach cancer

Бакулин¹,

Пирогов²,

Бакулина³

et al. 2018

Dok. gastroenterol.

View full text Add to dashboard Cite

Stomach cancer occupies the leading position both in the world and in Russia in terms of incidence and mortality. At the same time, it is considered to be a potentially preventable oncological disease. This review was designed to analyze risk factors of stomach cancer with special reference to the H. pylori infection. The possibilities of prevention and early diagnostics of gastric cancer are discussed. The optimal strategy for the prevention of gastric cancer is deemed to be the combination of eradication of H. pylori with endoscopic screening and observation. For Russia, it is urgent to develop a unified multidisciplinary approach to the prevention of gastric cancer at all stages of carcinogenesis.

show abstract

Genetic host factors in Helicobacter pylori -induced carcinogenesis: Emerging new paradigms

Cited by 75 publications

References 156 publications

Inhibition of autophagy enhances cinobufagin‑induced apoptosis in gastric cancer

Inhibition of autophagy enhances cinobufagin‑induced apoptosis in gastric cancer

Correlation of registered drug packs with Maastricht V/Florence Consensus Report and national treatment guidelines for management of Helicobacter pylori infection

Prophylaxis and early diagnosis of stomach cancer

Contact Info

Product

Resources

About